• Topic
    • COVID-19
    • New Drugs
    • Oncology
    • Metabolism
    • Neuroscience
    • Autoimmune Diseases
    • Infections
    • Rare/Orphan Diseases
    • Drug Safety
  • Section
    • Pharma & Biotech
    • Regulatory
    • Clinical Trials
    • Mergers & Acquisitions
    • Research
    • In the Pipeline
  • BioPharma Media
    • About Us
    • Our Team
    • Contact Us
    • Editorial Policy
    • Terms of Use
    • Privacy Policy
  • Facebook
  • Twitter
  • LinkedIn
  • Google News
Skip to content
  • Facebook
  • Twitter
  • LinkedIn
  • Google News
BioPharma Media

BioPharma Media

Biopharmaceutical industry analysis.
 Credible, reliable, equitable.

  • Topic
    • COVID-19
    • New Drugs
    • Oncology
    • Metabolism
    • Neuroscience
    • Autoimmune Diseases
    • Infections
    • Rare/Orphan Diseases
    • Drug Safety
  • Section
    • Pharma & Biotech
    • Regulatory
    • Clinical Trials
    • Mergers & Acquisitions
    • Research
    • In the Pipeline
  • BioPharma Media
    • About Us
    • Our Team
    • Contact Us
    • Editorial Policy
    • Terms of Use
    • Privacy Policy

COVID-19 treatment

Xocova: Powerful New Japanese Pill for Coronavirus Treatment
Posted inCOVID-19, Infections, New Drugs, Regulatory

Xocova: Powerful New Japanese Pill for Coronavirus Treatment

November 27, 2022December 5, 2022

Ensitrelvir by Shionogi & Co. is a highly effective antiviral drug that works just as well as Pfizer’s Paxlovid.

coronavirus Omicron
Posted inCOVID-19, Infections, Research

Omicron Treatment: Most Effective Drugs

August 31, 2022September 8, 2022

Efficacy of antivirals and monoclonal antibodies for outpatient treatment of COVID-19 infection with the Omicron variant of SARS-CoV-2 coronavirus.

Paxlovid (nirmatrelvir + ritonavir)
Posted inCOVID-19, Infections, Regulatory

Paxlovid for COVID-19 Treatment. All Details

August 24, 2022November 28, 2022

Paxlovid: treatment efficacy, “Paxlovid mouth”, COVID-19 rebound, management of Omicron variant, treatment resistance, generics, mechanism of action, price.

Evusheld: First Drug for Strong and Long-Lasting Protection Against Coronavirus
Posted inCOVID-19, Infections, New Drugs, Regulatory

Evusheld: First Drug for Strong and Long-Lasting Protection Against Coronavirus

June 8, 2022September 8, 2022

One dose of AstraZeneca’s monoclonal antibody cocktail protects against COVID-19 for six months or longer.

proxalutamide
Posted inClinical Trials, COVID-19, Infections

Kropsen: Strong New Pill to Treat COVID-19 Infection

April 11, 2022September 8, 2022

Oral proxalutamide by Chinese Kintor Pharmaceutical effectively treats COVID-19 in outpatients and inpatients.

Favipiravir to Treat COVID-19. Most Comprehensive Review in World
Posted inClinical Trials, COVID-19, Infections, Research

Favipiravir to Treat COVID-19. Most Comprehensive Review in World

March 5, 2022September 8, 2022

What benefit we should expect from favipiravir in the fight against coronavirus?

Upamostat: Oral Medication for COVID-19
Posted inClinical Trials, COVID-19, Infections

Upamostat: Oral Medication for COVID-19

March 3, 2022September 8, 2022

Upamostat by RedHill Biopharma prevents COVID-19 complications from developing followed by hospitalization or death.

Posts navigation

1 2 3 4 Older posts
BioPharma Media Logo
Biopharmaceutical industry analysis.
© 2023 BioPharma Media. Newspack by Automattic. The end-to-end solution. Privacy Policy
  • Facebook
  • Twitter
  • LinkedIn
  • Google News